Abraxane alone + Abraxane + Tigatuzumab
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Triple Negative Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Cancer
Trial Timeline
Mar 1, 2011 → Jun 1, 2017
NCT ID
NCT01307891About Abraxane alone + Abraxane + Tigatuzumab
Abraxane alone + Abraxane + Tigatuzumab is a phase 2 stage product being developed by Daiichi Sankyo for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01307891. Target conditions include Breast Cancer, Triple Negative Breast Cancer, Stage IV Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01307891 | Phase 2 | Completed |
Competing Products
20 competing products in Breast Cancer